BioNTech (NASDAQ:BNTX) CEO Sells $2,664,630.00 in Stock

by · The Markets Daily

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $98.69, for a total transaction of $2,664,630.00. Following the transaction, the chief executive officer owned 314,209 shares in the company, valued at $31,009,286.21. The trade was a 7.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

  • On Wednesday, September 30th, Ugur Sahin sold 32,000 shares of BioNTech stock. The stock was sold at an average price of $98.12, for a total value of $3,139,840.00.
  • On Monday, September 28th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.47, for a total transaction of $3,347,980.00.
  • On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The stock was sold at an average price of $98.99, for a total transaction of $3,860,610.00.
  • On Wednesday, September 23rd, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $99.40, for a total value of $2,982,000.00.
  • On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The shares were sold at an average price of $100.72, for a total value of $4,633,120.00.
  • On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total value of $3,227,730.00.
  • On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total transaction of $2,886,600.00.
  • On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
  • On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
  • On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total transaction of $3,280,660.00.

BioNTech Stock Performance

NASDAQ:BNTX opened at $98.30 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a 50 day moving average price of $98.56 and a 200 day moving average price of $94.96. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The stock has a market capitalization of $24.86 billion, a P/E ratio of -12.55 and a beta of 1.29.

BioNTech (NASDAQ:BNTX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter last year, the company earned ($1.60) earnings per share. The firm’s revenue for the quarter was down 59.5% on a year-over-year basis. Equities research analysts forecast that BioNTech SE Sponsored ADR will post -6.37 EPS for the current year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors have recently made changes to their positions in BNTX. Engineers Gate Manager LP raised its stake in shares of BioNTech by 17.3% in the second quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of BioNTech during the 2nd quarter valued at $39,000. Nykredit A S acquired a new position in BioNTech in the 2nd quarter valued at approximately $293,000. B. Metzler seel. Sohn & Co. AG increased its holdings in BioNTech by 66.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock valued at $1,020,000 after buying an additional 4,390 shares during the period. Finally, Headlands Technologies LLC acquired a new position in BioNTech in the second quarter worth about $2,520,000. Institutional investors own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BNTX. Wall Street Zen downgraded BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Canaccord Genuity Group cut their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating for the company in a report on Monday, August 31st. UBS Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, September 16th. Morgan Stanley lowered their target price on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $126.00.

Get Our Latest Report on BNTX

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.

Read More